Q&A Zealand Pharma 2019-05-29

	29/5 15:45 af Investorbro	What is the status on Elsiglutide? Is there an investigator sponsored phase 2 trial coming up?
	29/5 15:45 af Investorbro	When can we expect the first pre clinical data from the collaboration with Alexion?
	29/5 15:46 af Emmanuel Dulac	First, the discontinuation of elsiglutide was announced in March 2019, along with the selection of ZP 7570 as a new clinical candidate..
	29/5 15:48 af Emmanuel Dulac	Second, the Alexion-Zealand working teams are off to a good start. We hope to have data on the C3 complement inhibitor by the end of 2019 so that Phase 1 initiation could be possible next year. But there are three more candidates to this deal and more milestones attached to advancing them..
	29/5 15:49 af Emmanuel Dulac	And third, Boehringer Ingelheim will decide on development progress for GLP-1/GLU. We expect results from Phase 1 this year, which of course will inform if development will continue into Phase 2.
	29/5 15:50 af Stroka	Zealand Pharma has yet not found a new CFO. When do you expect to be able to announce this position occupied?
	29/5 15:51 af Emmanuel Dulac	Filling the CFO position has been one of my immediate tasks upon starting at Zealand, as well as a priority for the Board of Directors. We are in discussion with several candidates and hope to make an announcement as soon as possible .
	29/5 15:52 af Jakob440	Finally, does Zealand Pharma participate in Investordagen in Aarhus June 11th?
	29/5 15:53 af Emmanuel Dulac	Unfortunately, we will not participate in the June event this year. We are hoping to join Investordagen in Copenhagen this September.
	29/5 15:54 af Helge Larsen/PI-redaktør	Emmanuel Dulac..Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to to seeing you back here on ProInvestor.com after Q2.
	29/5 15:54 af Emmanuel Dulac	Thank you again for having me. I look forward to our next discussion.
	29/5 15:55 af Helge Larsen/PI-redaktør	This session is ended.